The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonnance imaging environment : a preliminary investigation of tolerability Robin L. Carhart-Harris et al., Journal of Psychopharmacology, 2010, 1-6 DOI: 10.1177/0269881110367445 Abstract This study sought to assess the tolerability of intravenously administered psilocybin in healthy, hallucinogen-experienced volunteers in a mock-magnetic resonance imaging environment as a preliminary stage to a controlled investigation using functional magnetic resonance imaging to explore the effects of psilocybin on cerebral blood flow and activity. The present pilot study demonstrated that up to 2 mg of psilocybin delivered as a slow intravenous injection produces short-lived but typical drug effects that [...]
Lire la suiteImplications for psychedelic-assisted psychotherapy : a functional magnetic resonance imaging study with psilocybin R. L. Carhart-Harris, R. Leech, T. M. Williams, D. Erritzoe, N. Abbasi, T. Bargiotas, P. Hobden, D. J. Sharp, J. Evans, A. Feilding, R. G. Wise and D. J. Nutt British Journal of Psychiatry, 2012, 200, 238-244. Doi : 10.1192/bjp.bp.111.103309 Background Psilocybin is a classic psychedelic drug that has a history of use in psychotherapy. One of the rationales for its use was that it aids emotional insight by lowering psychological defences. Aims To test the hypothesis that psilocybin facilitates access to personal memories and emotions by comparing subjective and neural responses to positive [...]
Lire la suiteFunctional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis Robin L. Carhart-Harris, Robert Leech, David Erritzoe, Tim M. Williams, James M. Stone, John Evans, David J. Sharp, Amanda Feilding, Richard G. Wise, and David J. Nutt Schizophrenia Bulletin, 2012, Volume 39, Issue 6, November 2013, Pages 1343–1351 doi : 10.1093/schbul/sbs117 Psilocybin is a classic psychedelic and a candidate drug model of psychosis. This study measured the effects of psilocybin on resting-state network and thalamo-cortical functional connectivity (FC) using functional magnetic resonance imaging (fMRI). Fifteen healthy volunteers received intravenous infusions of psilocybin and placebo in 2 task-free resting-state scans. Primary analyses focused on [...]
Lire la suiteNeural correlates of the psychedelic state as determined by fMRI studies with psilocybine Robin L. Carhart-Harris, David Erritzoe, Tim Williams, James M. Stone, Laurence J. Reed, Alessandro Colasanti, Robin J. Tyacke, Robert Leech, Andrea L. Malizia, Kevin Murphy, Peter Hobden, John Evans, Amanda Feilding, Richard G. Wise, and David J. Nutt PNAS, Proceedings of the National Academy of Sciences of the USA, 2012, 109, (6), 2138-2143. doi:10.1073/pnas.1119598109 www.pnas.org/lookup/suppl/doi:10.1073/pnas.1119598109/-/DCSupplemental. Abstract Psychedelic drugs have a long history of use in healing ceremonies, but despite renewed interest in their therapeutic potential, we continue to know very little about howthey work in the brain. Here we used psilocybin, a classic [...]
Lire la suitePeyote - Mescaline Scientific Papers AEDMP - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica Research conducted by : Juan Spuch & Genís Oña Divulgación de la Medicina Psicodélica. Castellarnau, 11 2º 1ª 43004 Tarragona Spain Tel. 675 55 33 44 Email: medicina.psicodelica@hotmail.com www.medicinapsicodelica.org Content _____________________________________ 1. What is peyote? 2. Scientific papers about peyote - mescaline arranged chronologically (1954-2012) - H. Denber & S. Merlis (1954). A Note on Some Therapeutic Implications of the Mescaline induced State - C. Landis & J. Clausen (1954). Certain Effects of Mescaline and Lysergic Acid on Psychological Functions - J. Cattell (1954). The Influence of Mescaline on Psychodynamic Material - W. Frederking (1955). Intoxicant [...]
Lire la suitePsychedelic Induced Transpersonal Experiences, Therapies, and Their Implications for Transpersonal Psychology Thomas B. Roberts and Michael J. Winkelman Chapter 25 - The Wiley-Blackwell Handbook of Transpersonal Psychology, First Edition. Edited by Harris L. Friedman and Glenn Hartelius. © 2013 John Wiley & Sons, Ltd. Published 2013 by John Wiley & Sons, Ltd. Psychedelics and other natural and synthetic substances have an ability to induce a range of transpersonal experiences. The predominance of spiritually-related experiences from these substances has led to the development of the concept of entheogen— reflecting their potential to produce an internal experience of communing with god. The similarity of the drug-induced transpersonal [...]
Lire la suitePsychiatry might need some psychedelic therapy Matthew W. Johnson International Review of Psychiatry, 2018, 30, 4, 285-290, DOI: 10.1080/09540261.2018.1509544 EDITORIAL Psychiatry might need some psychedelic therapy In historical and modern-day studies, psychedelic drugs have shown promise in managing a variety of psychiatric disorders, but their medical use has often raised controversies. The controversies have related to social, political, and legal challenges. History Although anthropological evidence suggests that classic psychedelic drugs (hereafter, ‘psychedelics’) have been used by various indigenous peoples as sacraments and healing agents before recorded history, in the mid-twentieth century they came to occupy a place at the cutting edge of psychiatric research (Johnson, Richards, & Griffiths, [...]
Lire la suiteLong-term follow-up of psilocybin-facilitated smoking cessation Johnson M.W., Garcia-Romeu A., Griffiths R.R. The American Journal of Drug and Alcohol Abuse, 2017, 43, (1), 55–60 http://dx.doi.org/10.3109/00952990.2016.1170135 Abstract Background : A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. Objectives : To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. Methods : The present [...]
Lire la suiteThe paradoxical psychological effects of lysergic acid diethylamide (LSD) R. L. Carhart-Harris, M. Kaelen, M. Bolstridge, T. M. Williams, L. T. Williams, R. Underwood, A. Feilding and D. J. Nutt Psychological Medicine, 2016, 46, 1379–1390. doi:10.1017/S0033291715002901 Background : Lysergic acid diethylamide (LSD) is a potent serotonergic hallucinogen or psychedelic that modulates consciousness in a marked and novel way. This study sought to examine the acute and mid-term psychological effects of LSD in a controlled study. Method : A total of 20 healthy volunteers participated in this within-subjects study. Participants received LSD (75 μg, intravenously) on one occasion and placebo (saline, intravenously) on another, in a [...]
Lire la suitePsychedelic Drugs in Biomedicine Evan J. KYZAR, Charles D. NICHOLS, Paul R. GAINETDINOV, David E. NICHOLS, Allan V. KALUEFF Trends in Pharmacological Sciences, 2017, 38, (1), 992-1005 https://doi.org/10.1016/j.tips.2017.08.003 Trends Psychedelic drugs profoundly alter human behavior, acting primarily via agonism at the 5-HT2A receptor in the brain. Research into the mechanisms of psychedelic drugs is experiencing a renaissance after years of stagnation. Animal models show that psychedelic drugs alter a number of crucial molecular mechanisms. Psychedelic drugs cause widespread changes in cognition and brain connectivity. Recent pilot studies show LSD and psilocybin are effective in treating psychiatric disorders and possibly other illnesses. Psychedelic biomedicine is rapidly emerging as an important area [...]
Lire la suite